News
What's happening in Alzheimer's care, research funding, and treatment — summarized simply, each item linked to the original reporting.
Free to read, “May need a subscription” and “Archived copy”: what they mean
Whether an article is free to read is a guess, not a test of your access. Each item is one of three:
- No label: free to read (339 of 393). The publisher’s page marks it free, or the outlet publishes free to read: Medical Xpress, ScienceDaily, NIH (incl. NIA and PMC), Alzheimer's Association, Alzheimer's News Today, NPR, Alzheimer's Disease International, or a .gov site.
- May need a subscription (16 of 393). The publisher’s own page marks the article as not free to read, or — when the page says nothing — the outlet sells subscriptions: The New York Times, STAT, Scientific American, The Washington Post, The Wall Street Journal, Financial Times, The Economist, Bloomberg, The Atlantic, The New Yorker, Wired, Los Angeles Times, The Boston Globe, The Times, The Telegraph, New Scientist, Endpoints News, Science. Each badge says which.
- “Free to read? Not known” (38 of 393). The outlet is on neither list and its page said nothing. We do not call these paywalled.
Archived copy links go to a copy the Internet Archive (web.archive.org) saved, dated the day it was saved. We show one only where the Internet Archive reported a working saved copy when we checked; an archived copy of a subscription article sometimes shows only its opening. 291 of 393 items have one.
STAT+: Dutch antitrust regulators probe Biogen over test for its MS drug
Dutch antitrust regulators are investigating allegations that Biogen may have abused its dominant position in the market for MS treatments and associated blood tests.
May need a subscription The publisher's page marks this article as not free to read (checked 11 Nov 2026).
Read at STAT News →Search for Alzheimer's drug unexpectedly finds possible biomarker
Researchers developed a drug for Alzheimer's disease and then discovered that the molecule already exists in human blood and is found at lower levels in cognitively impaired people. Now the authors are exploring the peptide as a biomarker as well as a treatment.
Read at Medical Xpress →Brain PET scans help select and monitor patients for new Alzheimer's drugs
Nuclear medicine is playing an increasingly important role in the diagnosis and treatment of Alzheimer's disease, helping clinicians visualize the biological changes associated with the condition and guide decisions about new therapies. …
Read at Medical Xpress →FDA Clears C2N Diagnostics' PrecivityAD2 — First Alzheimer's Blood Test for Adults With Cognitive Symptoms as Young as 40
The FDA cleared C2N Diagnostics' PrecivityAD2 mass-spectrometry blood test for adults as young as 40 with signs of cognitive impairment, showing 97.6% positive predictive value and 93.1% negative predictive value for amyloid pathology in a 1,142-person study.
Why it matters: Extends FDA-cleared blood testing to younger patients with early symptoms, broadening options beyond the Fujirebio test and expanding access to earlier, less invasive diagnosis.
Free to read? Not known for this outlet.
Read at C2N Diagnostics (via BioSpace) → Archived copy (7 Oct 2026), Internet ArchiveFollow new items in a feed reader: Atom feed.